

9 July 2013 EMA/HMPC/138317/2013 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on Ononis spinosa L., radix

Draft

Discussion in Working Party on Community monographs and Community	March 2013	
list (MLWP)	May 203	
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	0. 1010 2012	
for consultation	9 July 2013	
End of consultation (deadline for comments). Comments should be	15 December 2013	
provided using this template to hmpc.secretariat@ema.europa.eu		
Rediscussion in Working Party on Community monographs and		
Community list (MLWP)		
Adoption by Committee on Herbal Medicinal Products (HMPC)		

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional	
	use; Ononis spinosa L., Ononidis radix; Restharrow root	

BG (bălgarski): Гръмотрън, корен	LT (lietuvių kalba): Dirvenių šaknys
CS (čeština): jehlicový kořen	LV (latviešu valoda): Blaktenes sakne
DA (dansk): Krageklo	MT (malti): Gherq tal-Broxka
DE (Deutsch): Hauhechelwurzel	NL (nederlands): Kattendoornwortel
EL (elliniká):	PL (polski): Korzeń wilżyny
EN (English): Restharrow root	PT (português): Gatunha
ES (espanol): Gatuña, raiz de	RO (română):
ET (eesti keel): jooksjarohi	SK (slovenčina): koreň ihlice
FI (suomi): ruusuorakko, juuri	SL (slovenščina): korenina navadnega gladeža
FR (français): Bugrane, Arrête-boeuf	SV (svenska): busktörnerot
HU (magyar):	IS (íslenska):
HR (hrvatska):	NO (norsk):
IT (italiano): Ononide radice	

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu



An agency of the European Union

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on Ononis spinosa L., radix

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1,2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Ononis spinosa L., radix (Restharrow root)
	i) Herbal substance
	Not applicable.
	ii) Herbal preparations
	Comminuted herbal substance.

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints.
	The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. ² The material complies with the Ph. Eur. monograph (ref.: 01/2008:1879).

Well-established use	Traditional use
	Posology
	Adolescents, adults and elderly
	Herbal tea: 2 – 3 g of comminuted herbal substance in 150 ml of boiling water as a herbal infusion up to 3 - 4 times daily corresponding to the maximum daily dose of 12 g.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.

4.2. Posology and method of administration³

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.
	Conditions where a reduced fluid intake is recommended (e.g. severe cardiac or renal disease).

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children under 12 years of age has not been established due to lack of adequate data.
	To ensure an increase of the amount of urine, adequate fluid intake is required during the treatment.
	If urinary tract complaints worsen and symptoms such as fever, dysuria, spasm, or blood in the urine occur during the use of medicinal product, a doctor or a gualified health care practitioner

³ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

should be	e consulted.
-----------	--------------

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	None known.
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on genotoxicity have not been performed. Tests on reproductive toxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

9 July 2013